NASDAQ: KTRAKintara Therapeutics Inc Stock
$7.05+0.21 (+3.07%)
Updated Feb 6, 2023
KTRA Price
$7.05
Fair Value Price
$19.14
Market Cap
$11.39M
52 Week Low
$3.50
52 Week High
$42.00
P/E
-0.38x
P/B
1.18x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$21.29M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.37
Operating Cash Flow
-$22M
Beta
0.84
Next Earnings
Feb 9, 2023
Ex-Dividend
N/A
Next Dividend
N/A
KTRA Overview
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KTRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KTRA ($7.05) is undervalued by 63.17% relative to our estimate of its Fair Value price of $19.14 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KTRA ($7.05) is significantly undervalued by 63.17% relative to our estimate of its Fair Value price of $19.14 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KTRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KTRA due diligence checks available for Premium users.
Be the first to know about important KTRA news, forecast changes, insider trades & much more!
KTRA News
Valuation
KTRA fair value
Fair Value of KTRA stock based on Discounted Cash Flow (DCF)
Price
$7.05
Fair Value
$19.14
Undervalued by
63.17%
KTRA ($7.05) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KTRA ($7.05) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KTRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KTRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.38x
Industry
11.5x
Market
14.99x
KTRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.18x
Industry
5.06x
KTRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KTRA's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.6M
Profit Margin
0%
KTRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$13.2M
Liabilities
$3.6M
Debt to equity
0.37
KTRA's short-term assets ($8.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KTRA's short-term assets ($8.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KTRA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KTRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.4M
Investing
-$232.0k
Financing
$1.9M
KTRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KTRA vs Biotech Stocks
Kintara Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.